Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04707352
Other study ID # ESR-20-20594 - MODA study
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date February 8, 2021
Est. completion date March 26, 2023

Study information

Verified date February 2023
Source Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Dapagliflozin reduces the risk of de novo heart failure (HF) in diabetics and, recently, it has shown to improve the prognosis of patients with HF and reduced left ventricular ejection fraction (HFrEF), by preventing HF decompensations and cardiovascular death. The benefit showed by dapagliflozin in HFrEF was irrespective of diabetes status and glycemic control, which raises the question of which mechanisms are underlying apart from SGLT2 inhibition. In addition, the impact of dapagliflozin on cardiac remodeling parameters, as assessed by echocardiography and biomarkers, is not well established. In particular, left atrial (LA) remodeling represents a relevant prognostic marker, which has received a greater attention in the last years in the context of new imaging tools. The purpose of this study is to assess the effect of dapagliflozin therapy over a period of 6 months in LA remodeling parameters, including geometry and function, as well as complementary biomarkers in patients with chronic HF regardless left ventricular ejection fraction (LVEF). This protocol will allow for evaluation of improved understanding of the interplay between dapagliflozin and LA function , biomarkers, remodeling and outcomes, and will carefully assess such relationships within important cohorts of subjects, such as those with reduced and preserved LVEF. This protocol will also generate a biorepository of well-handled and carefully considered biomarkers, which will allow a better understanding of dapagliflozin mechanism of action.


Description:

The reduction of death and HF related events observed with dapagliflozin make necessary to clarify the mechanisms underlying these clinical benefits. Currently, dapagliflozin is indicated in patients with diabetes irrespective of the presence of HF. The initiation in patients with HF represents an opportunity to elucidate the effect of dapagliflozin on cardiac remodeling in this population. Therefore, we propose a study that aims to assess the effects of dapagliflozin in echocardiographic parameters of cardiac remodeling, with special interest in LA geometry and function, as well as in biomarkers reflecting expanded pathophysiological pathways. LA volume has shown to identify the progression of HF irrespective of LVEF and, therefore, it represents a meaningful measure of the cardiac impact of dapagliflozin in the entire spectrum of chronic HF.


Recruitment information / eligibility

Status Completed
Enrollment 162
Est. completion date March 26, 2023
Est. primary completion date March 26, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age > 18 years - Prior diagnosis of HF, with at least one hospitalization for HF at any time. - NYHA class I-IV. - LVEF available (echocardiogram or cardiac MRI) within the last 12 months prior to enrolment. - Treatment according with contemporary guidelines recommendations and with stable doses of oral loop diuretics for at least 4 weeks - NT-proBNP >600 pg/ml at screening (=400 pg/ml if hospitalized for HF within the previous 12 months; =900 pg/ml If concomitant AF at - Screening irrespective of time to last HF hospitalization). Exclusion Criteria: - Dapagliflozin or other SGLT2i at any time in prior 6 months. - Type 1 diabetes mellitus (T1D) - Estimated glomerular filtration rate < 30 ml/min/1.73 m2 as measured by the simplified Modification of Diet in Renal Disease (MDRD) formula at screening. - Symptomatic hypotension or systolic blood pressure (SBP) <95 mmHg on 2 consecutive measurements at screening. - Uncontrolled hypertension, defined as SBP >160 mmHg. - Current acute decompensated HF or hospitalization due to decompensated HF within 4 weeks prior to enrolment - The use of outpatient or inpatient i.v. diuretic therapy within 4 weeks prior to baseline. - Subjects who are currently receiving or have received inotropic agents within 12 weeks prior to baseline. - Myocardial infarction, unstable angina, stroke or transient ischemic attack within 12 weeks prior to enrolment - Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting or valvular repair/replacement within 12 weeks prior to enrolment or planned to undergo any of these operations after inclusion - Implantation of a cardiac resynchronization therapy (CRT) within 12 weeks prior to enrolment or intent to implant a CRT device - Previous cardiac transplantation or implantation of a ventricular assistance device (VAD) or similar device, or implantation expected after inclusion - HF due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy or uncorrected primary valvular disease - Symptomatic bradycardia or second or third degree heart block without a pacemaker - History of allergic reactions or intolerance to dapagliflozin, or other iSGLT2, or any other compound - History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within one year. - Hepatic impairment aspartate transaminase [AST] or alanine transaminase [ALT] >3x the upper limit of normal [ULN]; or total bilirubin >2x ULN at time of screening) - Women of child-bearing potential (ie, those who are not chemically or surgically sterilised or who are not post-menopausal) who are not willing to use a medically accepted method of contraception that is considered reliable in the judgment of the investigator or women who have a positive pregnancy test at enrollment or randomization or women who are breast-feeding - Participation in another clinical trial during the last month prior to enrolment - Inability of the patient, in the opinion of the investigator, to understand and/or comply with study medications, procedures and/or follow-up or any conditions that, in the opinion of the investigator, may render the patient unable to complete the study - Any concomitant disease limiting life expectancy in the following year (other than heart failure) - No possibility to give informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dapagliflozin
All eligible subjects will receive Dapagliflozin 10 mg each day. The study treatment will be provided for the duration of the trial from baseline (Day 1) through last visit (Day 180).

Locations

Country Name City State
Spain Hospital Clinico Universitario Virgen de la Arrixaca Murcia

Sponsors (2)

Lead Sponsor Collaborator
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia Spanish Society of Cardiology

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in LAVI from baseline to 6 months. Up to 6 months
Secondary Change in LAVI-min (minimal left atrial volume index) Up to 6 months
Secondary Change in LAEF (left atrial ejection) Up to 6 months
Secondary Change in LAFI (left atrial functional index) Up to 6 months
Secondary Change in LA reservoir, conduit and pump volumes, emptying fractions and strain rates Up to 6 months
Secondary Change in Left ventricular end-systolic volume index (LVESVi) Up to 6 months
Secondary Change in left ventricular mass index (LVMI) Change in ventricular end-diastolic volume index (LVEDVi) Up to 6 months
Secondary Change in global longitudinal strain (GLS) Up to 6 months
Secondary Change in tricuspid annular plane systolic Up to 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05654272 - Development of CIRC Technologies
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy